A systematic review of immune checkpoint inhibitor-related neurological adverse events and association with anti-neuronal autoantibodies

References

• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Mc D. Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system. Ther Adv Neurol Disord. 2018;11.
   Web of Science ®Google Scholar
• Johnson DB, Manouchehri A, Haugh AM, et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2019;7(1):134.
   PubMed Web of Science ®Google Scholar
• Pignolet BSL, Gebauer CMT, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies. OncoImmunology. 2013;2(12):e27384.
   PubMed Web of Science ®Google Scholar
• Höftberger R, Rosenfeld MR, Dalmau J. Update on neurological paraneoplastic syndromes. Curr Opin Oncol. 2015;27(6):489–495.
   PubMed Web of Science ®Google Scholar
• Weinmann SC, Pisetsky DS. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. Vol. 58. Oxford, England: Rheumatology; 2019. p. vii59–vii67.
   Google Scholar
• Yshii LM, Hohlfeld R, Liblau RS. Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat Rev Neurol. 2017;13(12):755–763.
   PubMed Web of Science ®Google Scholar
• Reynolds KL, Guidon AC. Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature. Oncologist. 2019;24(4):435–443.
   PubMed Web of Science ®Google Scholar
• Pan P, Haggiagi A. neurologic immune-related adverse events associated with immune checkpoint inhibition. Current Oncology Reports. 2019;21.
   Google Scholar
• Perrinjaquet C, Desbaillets N, Hottinger AF. Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy. Curr Opin Neurol. 2019;32(3):500–510.
   PubMed Web of Science ®Google Scholar
• Astaras C, De Micheli R, Moura B, et al. Neurological adverse events associated with immune checkpoint inhibitors: Diagnosis and management. Curr Neurol Neurosci Rep. 2018;18(1):3.
   PubMed Web of Science ®Google Scholar
• Touat M, Talmasov D, Ricard D, et al. Neurological toxicities associated with immune-checkpoint inhibitors. Curr Opin Neurol. 2017;30(6):659–668.
   PubMed Web of Science ®Google Scholar
• Schardt C, Adams MB, Owens T, et al. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007;7(1):16.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339(jul21 1):b2700. .
   PubMed Web of Science ®Google Scholar
• Gill A, Perez MA, Perrone CM, et al. A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes. J Neuroimmunol. 2019;334:576980.
   PubMed Web of Science ®Google Scholar
• Brown MP, Hissaria P, Hsieh AH, et al. Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy. J Neuroimmunol. 2017;305:16–18.
   PubMed Web of Science ®Google Scholar
• Burke M, Hardesty M, Downs W A case of severe encephalitis while on PD-1 immunotherapy for recurrent clear cell ovarian cancer. Gynecologic Oncology Reports. 2018;24.
   Google Scholar
• Kopecký J, Kubeček O, Geryk T, et al. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report. Journal of Medical Case Reports. 2018;12: 262.
   Google Scholar
• Läubli H, Hench J, Stanczak M, et al. Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade. J Immunother Cancer. 2017;5(1):46. .
   PubMed Web of Science ®Google Scholar
• Papadopoulos KP, Romero RS, Gonzalez G, et al. Anti-hu-associated autoimmune limbic encephalitis in a patient with PD-1 inhibitor-responsive myxoid chondrosarcoma. Oncologist. 2018;23(1):118–120.
   PubMed Web of Science ®Google Scholar
• Shah S, Dunn-Pirio A, Luedke M, et al. Encephalitis in two patients with lung adenocarcinoma. Case Rep Neurol Med. 2018;2018:2548528.
   PubMed Web of Science ®Google Scholar
• Williams TJ, Benavides DR, Patrice KA, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol. 2016;73(8):928–933. .
   PubMed Web of Science ®Google Scholar
• Danova Lopez AC, Fershko A. Myasthenia gravis and rhabdomyolysis in a patient with advanced renal cell cancer treated with nivolumab: A case report and review of the literature. British Journal of Medical and Health Research. 2015;2:2394–2967.
   Google Scholar
• Lc DC, Zuppa A, et al. Neuromuscular complications following targeted therapy in cancer patients. J Peripher Nerv Syst. 2019;1753:24.
   Web of Science ®Google Scholar
• Fellner A, Makranz C, Lotem M, et al. Neurologic complications of immune checkpoint inhibitors. J Neurooncol. 2018;137(3):601–609.
   PubMed Web of Science ®Google Scholar
• Kang KH, Grubb W, Sawlani K, et al. Immune checkpoint-mediated myositis and myasthenia gravis: a case report and review of evaluation and management. Am J Otolaryngol. 2018;39:642–645.
   Google Scholar
• Konstantina T, Konstantinos R, Anastasios K, et al. Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review. Lung Cancer. 2019;135:29–32.
   PubMed Web of Science ®Google Scholar
• Rao S, Lin L, Park JK, et al. Adverse effects in an advanced non-small-cell lung cancer patient treated with pembrolizumab. B71. CASE REPORTS IN THORACIC ONCOLOGY III: American Thoracic Society, 2018:A4051–A4051.
   Google Scholar
• Shirai T, Sano T, Kamijo F, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol. 2015;46(1):86–88. .
   PubMed Web of Science ®Google Scholar
• Algaeed M, Mukharesh L, Heinzelmann M, et al. Pearls & oy-sters: Pembrolizumab-induced myasthenia gravis. Neurology. 2018;91(14):e1365–e1367.
   PubMed Web of Science ®Google Scholar
• Fukumoto Y, Kuwahara M, Kawai S, et al. Acute demyelinating polyneuropathy induced by nivolumab. J Neurol Neurosurg. 2018;89(4):435.
   Web of Science ®Google Scholar
• Manousakis G, Koch J, Sommerville RB, et al. Multifocal radiculoneuropathy during ipilimumab treatment of melanoma. Muscle Nerve. 2013;48(3):440–444. .
   PubMed Web of Science ®Google Scholar
• Kamo H, Hatano T, Kanai K, et al. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report. BMC Neurol. 2019;19(1):184. .
   PubMed Web of Science ®Google Scholar
• Kao JC, Liao B, Markovic SN, et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol. 2017;74(10):1216–1222. .
   PubMed Web of Science ®Google Scholar
• Rhee K, Ko T. Pembrolizumab induced multiple immune related adverse events including myasthenia gravis, hepatitis and thyroiditis in a patient with thymoma. Reactions Weekly. J Immunother Cancer. 2019;1754(1):277.
   Google Scholar
• Danova Lopez AC, Fershko A. myasthenia gravis and rhabdomyolysis in a patient with advanced renal cell cancer treated with nivolumab: a case report and review of the literature. British Journal of Medical and Health Research. 2015;2.
   Google Scholar
• Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092.
   PubMed Web of Science ®Google Scholar
• Lancaster E. Paraneoplastic disorders. Continuum (Minneapolis, Minn.). Neuro-oncology. 2015;21(2):452–475.
   Google Scholar
• Rosenfeld MR, Dalmau J. Update on paraneoplastic neurologic disorders. Oncologist. 2010;15(6):603–617.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain. 2004;127(8):1831–1844.
   PubMed Web of Science ®Google Scholar
• Fujiwara S, Yoshimura H, Mimura N, et al. Cerebrospinal fluid characteristics of encephalitis associated with immune checkpoint inhibitors. J Neurol Sci. 2017;381:79.
   Web of Science ®Google Scholar
• Galmiche S, Lheure C, Kramkimel N, et al. Encephalitis induced by immune checkpoint inhibitors in metastatic melanoma: a monocentric retrospective study. J Eur Acad Dermatol Venereol. 2019;33(12):e440–e443. .
   PubMed Web of Science ®Google Scholar
• Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol. 2016;29(6):806–812.
   PubMed Web of Science ®Google Scholar
• Laserna A, Tummala S, Patel N, et al. Atezolizumab-related encephalitis in the intensive care unit: case report and review of the literature. SAGE open medical case reports. 2018;6:2050313X18792422–12050313X18792422.
   Google Scholar
• Kao JC, Brickshawana A, Liewluck T. Neuromuscular complications of programmed cell death-1 (PD-1) Inhibitors. Curr Neurol Neurosci Rep. 2018;18(10):63.
   PubMed Web of Science ®Google Scholar
• Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017;82:128–136.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017;89(11):1127–1134.
   PubMed Web of Science ®Google Scholar
• Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017;73:1–8.
   PubMed Web of Science ®Google Scholar
• Puwanant A, Isfort M, Lacomis D, et al. Clinical spectrum of neuromuscular complications after immune checkpoint inhibition. Neuromuscul Disord. 2019;29(2):127–133.
   PubMed Web of Science ®Google Scholar
• Lin L, Park JK, Ludwig D, et al. Adverse effects in an advanced non-small-cell lung cancer patient treated with pembrolizumab. B71. CASE REPORTS IN THORACIC ONCOLOGY III:A4051-A4051.
   Google Scholar
• Moreira A, Loquai C, Pföhler C, et al. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer. 2019;106:12–23.
   PubMed Web of Science ®Google Scholar
• Moslehi JJ, Salem JE, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933.
   PubMed Web of Science ®Google Scholar
• Behling J, Kaes J, Münzel T, et al. New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma. Melanoma Res. 2017;27(2):155–158.
   PubMed Web of Science ®Google Scholar
• Chen JH, Lee KY, Hu CJ, et al. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: a case report and literature review. Medicine (Baltimore). 2017;96: e9262.
   Google Scholar
• Kim J-S, Nam T-S, Kim J, et al. Myasthenia gravis and myopathy after nivolumab treatment for non-small cell lung carcinoma: a case report. Thorac Cancer. 2019;10(10):2045–2049.
   PubMed Web of Science ®Google Scholar
• Rota E, Varese P, Agosti S, et al. Concomitant myasthenia gravis, myositis, myocarditis and polyneuropathy, induced by immune-checkpoint inhibitors: a life–threatening continuum of neuromuscular and cardiac toxicity. eNeurologicalSci. 2019;14:4–5.
   PubMedGoogle Scholar
• Chen YH, Liu FC, Hsu CH, et al. Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: case report. Medicine (Baltimore). 2017;96(27):e7350.
   PubMed Web of Science ®Google Scholar
• Irie S, Saito T, Kanazawa N, et al. Association of anti-GM antibodies in Guillain-Barre syndrome with acute cytomegalovirus infection. J Neuroimmunol. 1996;68(1–2):19–26.
   PubMed Web of Science ®Google Scholar
• Kim JK, Kim YH, Yoon B-A, et al. Clinical heterogeneity of anti-GM2-ganglioside-antibody syndrome. J Clin Neurol. 2018;14(3):401–406.
   PubMed Web of Science ®Google Scholar
• Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann Oncol. 2011;22(4):991–993.
   PubMed Web of Science ®Google Scholar
• Gettings EJ, Hackett CT, Scott TF. Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. Mult Scler J. 2015;21(5):670.
   PubMed Web of Science ®Google Scholar
• Cao Y, Nylander A, Ramanan S, et al. CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment. Neurology. 2016;86(16):1553–1556.
   PubMed Web of Science ®Google Scholar
• Gerdes LA, Held K, Beltrán E, et al. CTLA4 as immunological checkpoint in the development of multiple sclerosis. Ann Neurol. 2016;80(2):294–300.
   PubMed Web of Science ®Google Scholar
• Yost MD, Chou CZ, Botha H, et al. Facial diplegia after pembrolizumab treatment. Muscle Nerve. 2017;56(3):E20–E21.
   PubMed Web of Science ®Google Scholar
• Jinnur P, Lim KG. Severe acute orthopnea: Ipilimumab-induced bilateral phrenic nerve neuropathy. Lung. 2015;193(4):611–613.
   PubMed Web of Science ®Google Scholar
• Maur M, Tomasello C, Frassoldati A, et al. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J clin oncol. 2012;30(6):e76–e78.
   PubMed Web of Science ®Google Scholar
• Graus F, Dalmau J. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2019;16(9):535–548.
   PubMed Web of Science ®Google Scholar